health source semaglutide for weight loss | Blog A new study suggests GLP-1s

PCAC member Elizabeth Rebello, a professor in the Department of Anesthesiology and Perioperative Medicine at the University of Texas MD Anderson Cancer Center, cited the "lack of efficacy data and randomized controlled trials" as her basis for her no vote

And thats the frustrating part

See how OptiMantra can help you to deliver high-quality, evidence-based obesity care by booking a demo or signing-up for a free trial

The starting dose in trials was usually low, often around 1 mg to 2 mg weekly , depending on the study design

Next, learn how personalized dosing with TrimRX can simplify and optimize your GLP-1 treatment plan

Rotate placement to avoid skin sensitivity